FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,125,704 | -58.6% | 10,908,351 | -7.0% | 0.00% | 0.0% |
| Q2 2023 | $55,803,260 | -10.7% | 11,723,374 | +7.0% | 0.00% | -50.0% |
| Q1 2023 | $62,477,397 | -22.3% | 10,960,947 | +37.5% | 0.00% | 0.0% |
| Q4 2022 | $80,443,039 | -54.1% | 7,972,551 | +2.0% | 0.00% | -60.0% |
| Q3 2022 | $175,133,000 | -8.9% | 7,814,980 | +0.7% | 0.01% | 0.0% |
| Q2 2022 | $192,241,000 | -35.5% | 7,757,940 | +0.9% | 0.01% | -28.6% |
| Q1 2022 | $298,187,000 | -33.6% | 7,691,172 | +0.2% | 0.01% | -30.0% |
| Q4 2021 | $449,109,000 | -0.6% | 7,675,787 | +0.6% | 0.01% | -9.1% |
| Q3 2021 | $452,012,000 | -31.2% | 7,626,346 | +0.7% | 0.01% | -31.2% |
| Q2 2021 | $657,060,000 | +6.6% | 7,570,681 | +1.3% | 0.02% | -5.9% |
| Q1 2021 | $616,358,000 | -0.0% | 7,475,537 | +10.3% | 0.02% | -5.6% |
| Q4 2020 | $616,376,000 | +145.7% | 6,778,587 | +8.0% | 0.02% | +125.0% |
| Q3 2020 | $250,855,000 | +43.4% | 6,276,062 | +23.1% | 0.01% | +33.3% |
| Q2 2020 | $174,932,000 | +142.3% | 5,098,551 | +56.8% | 0.01% | +100.0% |
| Q1 2020 | $72,197,000 | +18.1% | 3,250,622 | +4.0% | 0.00% | +50.0% |
| Q4 2019 | $61,151,000 | +29.0% | 3,124,769 | +2.4% | 0.00% | 0.0% |
| Q3 2019 | $47,403,000 | -14.4% | 3,052,352 | +11.9% | 0.00% | 0.0% |
| Q2 2019 | $55,378,000 | +15.8% | 2,727,990 | +0.2% | 0.00% | 0.0% |
| Q1 2019 | $47,823,000 | +46.6% | 2,721,844 | +7.1% | 0.00% | +100.0% |
| Q4 2018 | $32,613,000 | -18.2% | 2,541,990 | +3.8% | 0.00% | -50.0% |
| Q3 2018 | $39,882,000 | +61.9% | 2,448,279 | +12.7% | 0.00% | +100.0% |
| Q2 2018 | $24,636,000 | +38.9% | 2,172,451 | +19.5% | 0.00% | 0.0% |
| Q1 2018 | $17,741,000 | +99.0% | 1,817,721 | +24.6% | 0.00% | – |
| Q4 2017 | $8,916,000 | +75.5% | 1,459,136 | +13.7% | 0.00% | – |
| Q3 2017 | $5,080,000 | +24.0% | 1,282,993 | +1.5% | 0.00% | – |
| Q2 2017 | $4,096,000 | -22.1% | 1,264,281 | +9.4% | 0.00% | – |
| Q1 2017 | $5,258,000 | +231.5% | 1,155,679 | +82.9% | 0.00% | – |
| Q4 2016 | $1,586,000 | -26.1% | 631,995 | -8.1% | 0.00% | – |
| Q3 2016 | $2,145,000 | +91.9% | 687,693 | +4.6% | 0.00% | – |
| Q2 2016 | $1,118,000 | -2.3% | 657,573 | +3.5% | 0.00% | – |
| Q1 2016 | $1,144,000 | -18.2% | 635,475 | +53.0% | 0.00% | – |
| Q4 2015 | $1,399,000 | -99.1% | 415,243 | -91.8% | 0.00% | -100.0% |
| Q3 2015 | $148,487,000 | +6705.1% | 5,060,786 | +1400.7% | 0.01% | – |
| Q2 2015 | $2,182,000 | +147.1% | 337,238 | +86.7% | 0.00% | – |
| Q1 2015 | $883,000 | +2.1% | 180,638 | +5.1% | 0.00% | – |
| Q4 2014 | $865,000 | -2.1% | 171,938 | 0.0% | 0.00% | – |
| Q3 2014 | $884,000 | -5.8% | 171,938 | +15.7% | 0.00% | – |
| Q2 2014 | $938,000 | -35.2% | 148,606 | 0.0% | 0.00% | – |
| Q1 2014 | $1,447,000 | +1147.4% | 148,606 | +702.1% | 0.00% | – |
| Q4 2013 | $116,000 | – | 18,526 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |